Durable Response after Olaparib Treatment for Perihilar Cholangiocarcinoma with Germline BRCA2 Mutation
Oncology Research and Treatment · 2023
DOI: 10.1159/000529919 ↗Kurz gefasst
Fallbericht in der Zeitschrift Oncology Research and Treatment, 2023. Verfasst von Bruno Almeida Costa und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Icahn School of Medicine at Mount Sinai (Morningside/West), New York, New York, USA, bruno.costa@mountsinai.org. Hauptthemen laut MEDLINE: Klatskin Tumor, Ovarian Neoplasms, Bile Duct Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
Introduction
Despite major advances in surveillance and management, advanced cholangiocarcinoma (CCA) still carries a dismal prognosis. In recent years, several actionable genomic alterations in pancreatobiliary malignancies have been identified. For instance, homologous recombination deficiency (HRD) has been considered a predictive biomarker of clinical response to platinum and poly (ADP-ribose) polymerase (PARP) inhibitors. Case Report: A 53-year-old man with a stage 3 (T4N0M0) BRCA2-mutant CCA developed intolerable toxicity after 44 cycles of gemcitabine/cisplatin. In light of his HRD positivity, treatment was switched to single-agent olaparib. The patient showed a partial radiological response, which was maintained after 8 months of olaparib discontinuation (progression-free survival >36 months).
Conclusion
Given the durable response observed, olaparib can be a valuable therapeutic tool in BRCA-mutant CCAs. Ongoing and future clinical trials are needed to confirm the role of PARP inhibition in similar patients and to define the clinicopathological and molecular profile of the individuals most likely to benefit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Icahn School of Medicine at Mount Sinai (Morningside/West), New York, New York, USA, bruno.costa@mountsinai.org.
- Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Department of Medicine, Weill Medical College of Cornell University, New York, New York, USA.
Zitieren
APA
Costa, B. A., Tallón de Lara, P., Park, W., Keane, F., Harding, J. J., & Khalil, D. N. (2023). Durable Response after Olaparib Treatment for Perihilar Cholangiocarcinoma with Germline BRCA2 Mutation. Oncology Research and Treatment. https://doi.org/10.1159/000529919
Vancouver
Costa BA, Tallón de Lara P, Park W, Keane F, Harding JJ, Khalil DN. Durable Response after Olaparib Treatment for Perihilar Cholangiocarcinoma with Germline BRCA2 Mutation. Oncology Research and Treatment. 2023. doi:10.1159/000529919
BibTeX
@article{Costa2023,
author = {Costa, Bruno Almeida and Tallón de Lara, Paulino and Park, Wungki and Keane, Fergus and Harding, James J and Khalil, Danny N},
title = {Durable Response after Olaparib Treatment for Perihilar Cholangiocarcinoma with Germline BRCA2 Mutation},
journal = {Oncology Research and Treatment},
year = {2023},
doi = {10.1159/000529919}
}
EUVIMED